Prophylactic Endobronchial Tranexamic Acid to Reduce Bleeding in Transbronchial Cryobiopsy
- Conditions
- Hemorrhage LungEndobronchial Mass
- Registration Number
- NCT06266546
- Lead Sponsor
- Youssef Yammine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria:<br><br> - Age =18<br><br> - Signed informed consent<br><br> - Receiving a transbronchial cryobiopsy<br><br>Exclusion Criteria:<br><br> - Age below 18<br><br> - Pregnancy<br><br> - Bleeding diathesis (INR >1.5 or known hematological problems)<br><br> - Subarachnoid hemorrhage<br><br> - Any active bleeding (any site)<br><br> - Decompensated liver disease<br><br> - Active intravascular clotting<br><br> - Prior VTE<br><br> - On oral contraceptive therapy<br><br> - Platelet count less than 50,000<br><br> - Use of antiplatelet medication other than low-dose aspirin within 5 days of<br> procedure<br><br> - Use of therapeutic anticoagulation within the last 24 hrs<br><br> - Known severe pulmonary hypertension (pulmonary artery systolic pressure > 60 mmHg)<br><br> - Chronic renal failure (estimated GFR below 30 mL/min)<br><br> - Allergy or hypersensitivity to tranexamic acid or any of its ingredients<br><br> - Prisoners<br><br> - Comfort care planned or initiated within 72 hours of admission
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Major Hemorrhage
- Secondary Outcome Measures
Name Time Method Early termination of the procedure due to bleeding;Rate of intermediate hemorrhage;Rate of minor hemorrhage;Inadequate tissue sampling due to bleeding;Graded use of other measures to control bleeding (not prophylactic);Unplanned hospital admission for bleeding complications;Acute cardiovascular side effects;All cause 28 day mortality